Aminoglycoside-induced vestibular injury: Maintaining a sense of balance

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1282-1289

  Ariano, Robert E ^a,b   Zelenitsky, Sheryl A ^b   Kassum, Diamond A ^b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Aminoglycoside; Monitoring; Vestibular toxicity

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; EAR DROPS; FREE RADICAL; GENTAMICIN; GLUTATHIONE; NETILMICIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BALANCE DISORDER; COGNITIVE DEFECT; DIZZINESS; DRUG MEGADOSE; DRUG MONITORING; EARLY DIAGNOSIS; ELECTRONYSTAGMOGRAPHY; ENDOCARDITIS; HEADACHE; HEARING LOSS; HEMODIALYSIS; HUMAN; INCIDENCE; LOADING DRUG DOSE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSCILLOPSIA; OSTEOMYELITIS; OTOTOXICITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TINNITUS; VERTIGO; VESTIBULAR DISORDER; VISUAL DISORDER; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; HUMANS; INCIDENCE; RISK FACTORS; VESTIBULAR DISEASES;

EID: 50249144471     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L001     Document Type: Review

References (38)

1. English WP, Williams MD. Should aminoglycoside antibiotics be abandoned? Am J Surg 2000;180:512-6.
2. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000; 5:3-22.
3. Priuska E, Schacht J. Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol 1995;50:1749-52.
4. Forge A, Li L. Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hearing Res 2000;139:97-115.
5. Song BB, Sha SH, Schacht J. Iron chelators protect from aminoglycoside-induced cochleo- and vestibule-toxicity. Free Radic Biol Med 1998; 25:189-95.
6. Sha SH, Taylor R, Forge A, et al. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hearing Res 2001;155:1-8.
7. Rybak LP. Aminoglycoside antibiotics. In: Cummings CW Jr, Haughey BH, Thomas JR, et al., eds. Cummings otolaryngology: head and neck surgery. 4th ed. Philadelphia, PA: Elsevier, 2005:1175-9.
8. Moravec WJ, Peterson EH. Differences between stereocilia numbers on Type I and Type II vestibular hair cells. J Neurophysiol 2004;92:3153-60.
9. Tanyeri H, Lopez I, Honrubia V. Histological evidence for hair cell regeneration after ototoxic cell destruction with local application of gentamicin in the chinchilla crista ampullaris. Hearing Res 1995;89:194-202.
10. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77:1492-500.
11. Fee WE. Aminoglycoside ototoxicity in the human. Laryngoscope 1980;40:1-19.
12. Black FO, Peterka RJ, Elardo SM. Vestibular reflex changes following aminoglycoside induced ototoxicity. Laryngoscope 1987;97:582-6.
13. Minor L. Gentamicin-induced bilateral vestibular hypofunction. JAMA 1998;279:541-4.
14. Lerner SA, Seligsohn R, Matz GJ. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med 1977;62:919-23.
15. Tjernström O, Denneberg T, Harris S, et al. Ototoxicity of netilmicin. Acta Otolaryngol 1982;94:421-9.
16. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity: a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(suppl A):9-22.
17. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986;80(suppl 6B):98-104.
18. Proctor L, Petty B, Lietman P, et al. A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin. Laryngoscope 1987;97:1443-9.
19. de Vries PJ, Verkooyen RP, Leguit P, et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-8.
20. Nordstrom L, Rinberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73
21. Gendeh BS, Said H, Gibb AG, et al. Gentamicin ototoxicity in continuous ambulatory peritoneal dialysis. J Laryngol Otol 1993;107:681-5.
22. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia, PA: Churchill Livingstone, 2000:307-36.
23. Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004;25:559-69.
24. Halmagyi GM, Fattore CM, Curthoys IS, et al. Gentamicin vestibulotoxicity. Otolaryngol Head Neck Surg 1994;111:571-4.
25. Gatell JM, Ferran F, Araujo V, et al. Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother 1987;31:1383-7.
26. Fischel-Ghodsian N, Prezant TR, Chaltraw WE, et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. Am J Otolaryngol 1997;18:173-8.
27. Pandya A, Xia X, Raduaabazar J, et al. Mutation in the mitochondrial 12S rRNA gene in two families from Mongolia with matrilineal aminoglycoside ototoxicity. J Med Genet 1997;34:169-72.
28. Dulon D, Aurousseau C, Erre JP, Aran JM. Relationship between the nephrotoxicity and ototoxicity induced by gentamicin in the guinea pig. Acta Otolaryngologica 1988;106:219-25.
29. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother 1989;24:281-93.
30. Ferriols-Lisart R, Alms-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141-50.
31. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996;312:338-45.
32. Mars RL, Moles K, Pope K, et al. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. Adv Perit Dial 2000;16:280-4.
33. Chong TK, Piraino B, Bernardini J. Vestibular toxicity due to gentamicin in peritoneal dialysis patients. Perit Dial Int 1991;11:152-5.
34. Marais J, Rutka JA. Ototoxicity and topical eardrops. Clin Otolaryngol 1998;23:360-7.
35. Edson RS, Brey RH, McDonald TJ, et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004;79:1185-91.
36. Ahya VN, Doyle AM, Mendez JD, et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-5.
37. Carr D, Shalansky K, Marra F, Mallinson A. Pharmacist performance of the DIE test to assess aminoglycoside vestibulotoxicity. Can J Hosp Pharm 2003;56:267-72.
38. Longridge NS, Mallinson AI. The dynamic illegible e-test: a technique for assessing the vestibulo-ocular reflex. Acta Otolaryngol 1987;103: 273-9.